Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GEOFFREY L CHUPP

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1811970577
CMS profile
309470
Location
NEW HAVEN, CT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$135,672.32

90 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GEOFFREY L CHUPP

NPI 1811970577 · CMS profile ID 309470

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

NEW HAVEN, CT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1811970577?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GEOFFREY L CHUPP, NPI 1811970577, CMS profile ID 309470. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1811970577?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). GEOFFREY L CHUPP, NPI 1811970577, CMS profile ID 309470. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1811970577?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
GEOFFREY L CHUPP, NPI 1811970577, CMS profile ID 309470, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1811970577?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

90 matching records · $135,672.32 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 90 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–90 of 90.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $1,343.0008/16/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735904051 CMS
GENZYME CORPORATION $1,132.0008/13/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744098211 CMS
GlaxoSmithKline, LLC. $600.0008/04/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738808065 CMS
AstraZeneca Pharmaceuticals LP $1,611.0007/21/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736126909 CMS
Regeneron Healthcare Solutions, Inc. $2,972.0007/14/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 724417097 CMS
Regeneron Healthcare Solutions, Inc. $28.1407/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 724417095 CMS
AstraZeneca Pharmaceuticals LP $2,148.0007/02/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736251123 CMS
GlaxoSmithKline, LLC. $2,925.0007/02/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738682635 CMS
AstraZeneca Pharmaceuticals LP $2,148.0006/24/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735793095 CMS
GlaxoSmithKline, LLC. $975.0006/19/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738806603 CMS
GENZYME CORPORATION $1,132.0006/11/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744098127 CMS
AstraZeneca Pharmaceuticals LP $1,611.0005/20/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736130769 CMS
AstraZeneca Pharmaceuticals LP $1,074.0005/20/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736414599 CMS
GENZYME CORPORATION $4,728.0005/15/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744098143 CMS
AstraZeneca Pharmaceuticals LP $2,148.0005/13/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736107347 CMS
GlaxoSmithKline, LLC. $3,250.0004/23/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738590631 CMS
GlaxoSmithKline, LLC. $3,250.0004/23/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738624189 CMS
AstraZeneca Pharmaceuticals LP $2,416.5004/20/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736154001 CMS
GlaxoSmithKline, LLC. $33.0004/09/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738893445 CMS
AstraZeneca Pharmaceuticals LP $1,600.0003/29/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736101133 CMS
GlaxoSmithKline, LLC. $338.7503/26/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738889139 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $820.0003/09/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720569473 CMS
GlaxoSmithKline, LLC. $1,200.0003/09/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738689649 CMS
GlaxoSmithKline, LLC. $3,600.0003/04/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738735375 CMS
GlaxoSmithKline, LLC. $4,000.0002/28/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738611669 CMS
Inari Medical, Inc. $68.4402/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752422817 CMS
Bard Peripheral Vascular, Inc. $140.2402/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748105869 CMS
GlaxoSmithKline, LLC. $3,600.0002/25/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738661349 CMS
Philips Electronics North America Corporation $75.1002/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751380999 CMS
GENZYME CORPORATION $1,132.0002/21/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788973593 CMS
GlaxoSmithKline, LLC. $1,560.4502/20/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738575057 CMS
GlaxoSmithKline, LLC. $97.1602/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738755941 CMS
GENZYME CORPORATION $24.5302/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744098083 CMS
GENZYME CORPORATION $2,972.0002/10/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744098085 CMS
GlaxoSmithKline, LLC. $1,339.5802/06/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738652409 CMS
GlaxoSmithKline, LLC. $110.2902/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738834761 CMS
GENZYME CORPORATION $125.0002/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744098079 CMS
GENZYME CORPORATION $3,396.0002/05/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744098081 CMS
GlaxoSmithKline, LLC. $3,600.0001/16/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738761039 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,800.0001/08/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747146829 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $294,814.35 222
PY2020 $135,672.32 90
PY2021 $238,712.59 163
PY2022 $234,108.18 156
PY2023 $148,399.55 75
PY2024 $110,299.09 59
PY2025 $73,010.21 56

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,199.85 14
PY2025 Principal investigator $342,498.38 46
PY2024 Principal investigator $242,309.60 22
PY2023 Recipient $1,250.00 1
PY2023 Principal investigator $285,241.76 11
PY2022 Principal investigator $65,306.17 24
PY2021 Principal investigator $296,612.65 49
PY2020 Principal investigator $232,090.41 54
PY2019 Principal investigator $397,375.48 72

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

60 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GlaxoSmithKline, LLC. $25,984.00 12/24/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192185226
Principal investigator 1 GlaxoSmithKline, LLC. $25,481.00 12/11/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192187458
Principal investigator 1 GlaxoSmithKline, LLC. $4,374.54 12/11/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192187468
Principal investigator 1 GlaxoSmithKline, LLC. $7,223.00 12/11/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192187472
Principal investigator 1 GlaxoSmithKline, LLC. $2,050.00 12/11/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192187477
Principal investigator 1 AstraZeneca Pharmaceuticals LP $10,378.30 12/10/2025 Non-covered Recipient Entity
YALE UNIVERSITY
The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibod No dispute reported 06/30/2026 1185537607
Principal investigator 1 GlaxoSmithKline, LLC. $4,965.00 11/21/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192189365
Principal investigator 1 GlaxoSmithKline, LLC. $41,595.00 11/20/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192189345
Principal investigator 1 GlaxoSmithKline, LLC. $1,674.00 10/22/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192098019
Principal investigator 1 GlaxoSmithKline, LLC. $390.00 10/22/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192150787
Principal investigator 1 GlaxoSmithKline, LLC. $2,634.00 10/08/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192187482
Principal investigator 1 GlaxoSmithKline, LLC. $6,555.00 09/08/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192187484
Principal investigator 1 GlaxoSmithKline, LLC. $1,235.00 08/21/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192187857
Principal investigator 1 AstraZeneca Pharmaceuticals LP $58,566.07 08/13/2025 Non-covered Recipient Entity
YALE SCHOOL OF MEDICINE DEPARTMENT OF ORTHOPAEDICS AMD REHABILITATION
Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 No dispute reported 06/30/2026 1185537599
Principal investigator 1 GlaxoSmithKline, LLC. $14,159.00 08/01/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192189354
Principal investigator 1 GlaxoSmithKline, LLC. $4,390.00 07/25/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192097987
Principal investigator 1 GlaxoSmithKline, LLC. $11,536.00 06/16/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192097980
Principal investigator 1 GlaxoSmithKline, LLC. $4,875.00 05/07/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192150796
Principal investigator 1 GlaxoSmithKline, LLC. $13,206.00 05/05/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192098026
Principal investigator 1 GlaxoSmithKline, LLC. $2,816.37 04/24/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192187464
Principal investigator 1 GlaxoSmithKline, LLC. $1,200.00 04/14/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192187853
Principal investigator 1 GlaxoSmithKline, LLC. $1,756.00 04/04/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192097992
Principal investigator 1 GlaxoSmithKline, LLC. $1,452.00 04/04/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192150781
Principal investigator 1 GlaxoSmithKline, LLC. $1,556.00 04/04/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192187841
Principal investigator 1 GlaxoSmithKline, LLC. $1,556.00 04/04/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192187848
Principal investigator 1 GlaxoSmithKline, LLC. $1,538.00 04/04/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192189350
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,650.00 03/21/2025 Non-covered Recipient Entity
YALE SCHOOL OF MEDICINE DEPARTMENT OF ORTHOPAEDICS AMD REHABILITATION
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) (COURSE) No dispute reported 06/30/2026 1185537605
Recipient GlaxoSmithKline, LLC. $36.31 03/18/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192151292
Recipient GlaxoSmithKline, LLC. $46.20 03/18/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192151297
Recipient GlaxoSmithKline, LLC. $82.04 03/18/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192151301
Principal investigator 1 GlaxoSmithKline, LLC. $1,538.00 03/07/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192097975
Principal investigator 1 GlaxoSmithKline, LLC. $2,134.00 03/07/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192097997
Principal investigator 1 GlaxoSmithKline, LLC. $1,538.00 03/07/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192098003
Principal investigator 1 GlaxoSmithKline, LLC. $1,472.00 03/07/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192098011
Principal investigator 1 GlaxoSmithKline, LLC. $3,004.00 03/07/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192187844
Principal investigator 1 GlaxoSmithKline, LLC. $2,134.00 03/07/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192187864
Principal investigator 1 GlaxoSmithKline, LLC. $3,004.00 03/07/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192187868
Principal investigator 1 GlaxoSmithKline, LLC. $2,115.00 03/07/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192189336
Principal investigator 1 GlaxoSmithKline, LLC. $1,452.00 03/07/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192189370
Principal investigator 1 GlaxoSmithKline, LLC. $1,556.00 03/07/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192189374
Principal investigator 1 AstraZeneca Pharmaceuticals LP $29,711.80 02/24/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Multicenter,Single arm,Open label,Post Authorization,Phase 4 Effectiveness and Safety Study of Tezepelumab in Adult and Adolescent Participants with Severe Asthma including Several Under Studied Populations in the United States No dispute reported 06/30/2026 1185537601
Principal investigator 1 AstraZeneca Pharmaceuticals LP $17,139.30 02/24/2025 Non-covered Recipient Entity
YALE NEW HAVEN HEALTH SYSTEM
The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibod No dispute reported 06/30/2026 1185537603
Principal investigator 1 GlaxoSmithKline, LLC. $1,338.00 02/07/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192150791
Principal investigator 1 GlaxoSmithKline, LLC. $1,338.00 02/07/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192187487
Principal investigator 1 GlaxoSmithKline, LLC. $1,537.00 02/07/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192187490
Principal investigator 1 GlaxoSmithKline, LLC. $2,134.00 02/07/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192187836
Principal investigator 1 GlaxoSmithKline, LLC. $3,004.00 02/07/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192187861
Principal investigator 1 GlaxoSmithKline, LLC. $1,472.00 02/07/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192189340
Recipient GlaxoSmithKline, LLC. $79.69 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192150800
Recipient GlaxoSmithKline, LLC. $50.38 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192150804
Recipient GlaxoSmithKline, LLC. $45.71 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192150808
Recipient GlaxoSmithKline, LLC. $444.76 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192150812
Recipient GlaxoSmithKline, LLC. $232.00 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192150817
Recipient GlaxoSmithKline, LLC. $46.76 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192150821
Recipient GlaxoSmithKline, LLC. $59.81 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192151283
Recipient GlaxoSmithKline, LLC. $427.20 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192151288
Recipient GlaxoSmithKline, LLC. $293.25 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192151305
Recipient GlaxoSmithKline, LLC. $293.25 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192151307
Recipient GlaxoSmithKline, LLC. $62.49 01/15/2025 Covered Recipient Physician A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192151311
Principal investigator 1 GlaxoSmithKline, LLC. $9,082.00 01/13/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192189359